framycetin has been researched along with oxandrolone in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (40.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Diament, J; Forti, N; Giannini, SD | 1 |
| Fumagalli, R; Paoletti, R; Sirtori, C | 1 |
2 review(s) available for framycetin and oxandrolone
| Article | Year |
|---|---|
[Therapeutic orientation in the hyperlipidemias].
Topics: Cholestyramine Resin; Dextrothyroxine; Humans; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Neomycin; Nicotinic Acids; Oxandrolone; Probucol; Sitosterols; Triglycerides | 1979 |
Hypolipidemic drugs.
Topics: Aminosalicylic Acids; Androgens; Bile Acids and Salts; Butyrates; Cellulose; Cholestyramine Resin; Clofibrate; Contraceptives, Oral; Female; Gonadal Steroid Hormones; Halofenate; Humans; Hyperlipidemias; Hypolipidemic Agents; Intestinal Absorption; Lignin; Lipid Metabolism; Lipid Mobilization; Male; Nafenopin; Neomycin; Nicotinic Acids; Oxandrolone; Probucol; Progestins; Sitosterols; Sterols; Thyroxine; Triglycerides | 1973 |
3 other study(ies) available for framycetin and oxandrolone
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |